Explore this test

  • Test Details
  • Lab Values
  • Clinical Significance
  • Treatment Options
DOWNLOAD SPECIMEN PREP FLYER

Explore this test

Test Code 87103

Test Details

Polygenic Risk Map™- Female Complete

Boston Heart’s Polygenic Risk Map test is a genetic test that leverages Polygenic Risk Score (PRS) analysis and reporting. The resulting risk scores provide clinical insights into a variety of important health conditions.

Methodology

Illumina Infinium Global Screening Array technology

Patient Preparation

None

Preferred Specimen

Saliva

Alternate Specimen

Whole blood

Transport Temperature

Room temperature

Stability

6 months at room temperature

Lab Values

Lab Values

Polygenic Risk Map™- Female Complete

Polygenic risk scores included in the Female Complete Panel:

  • Coronary Artery Disease (CAD) – Leading cause of death.
  • Atrial Fibrillation – 5-fold increase in stroke risk.
  • Type 2 Diabetes – 3-fold increase in CAD risk.
  • Hypertension – Causes CAD, stroke, and kidney disease.
  • BMI – Increases risk of CAD, diabetes and some cancers.
  • Triglycerides -Increases risk of CAD and pancreatitis.
  • Low HDL Cholesterol – Increases risk of CAD.
  • High LDL Cholesterol – Increases risk of CAD.
  • Lipoprotein (a) – Increases risk of CAD and aortic stenosis.
  • Alzheimer`s Disease – The leading cause of dementia.
  • Inflammatory Bowel Disease (IBD) – Ulcerative colitis and Crohn’s disease risk.
  • Breast Cancer – A leading cause of cancer in women.
  • Osteoporosis – A common cause of bone fractures.
  • Early Menopause – Risk of menopause before age 45.
  • Ancestry – Based on 26 global populations.
Test Details
Clinical Significance

Clinical Significance

Polygenic Risk Map™- Female Complete

  • Risk scores are determined by numerous well-studied genetic variations, and allow for impactful and targeted application of genomic testing to personalized medicine.
  • High-risk individuals generally have a substantially increased relative genetic risk for these conditions as compared to low-risk subjects.
  • Because lifetime risk of these conditions are also substantially influenced by environment, lifestyle, and medical care, a greater understanding of genetic risks may lead to greater preventive efforts.
  • Cost effectiveness studies suggest that providers can reduce cardiovascular events and healthcare system costs by using polygenic risk scores in appropriate patients.1
  • This type of testing is meant to augment rather than replace standard risk factor assessments for cardiovascular disease, breast cancer, prostate cancer or other conditions.

References:

  1. Mujwara D, Henno G, Vernon ST, et al. Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-Enhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis Study. J Am Heart Assoc. 2022;11(12):e025236
Lab Values
Treatment Options

Treatment Options

Polygenic Risk Map™- Female Complete

Genome-guided prevention by personalization of:

  • Dietary choices
  • Physical activity
  • Environmental factors
  • Medical care and screening
  • Medication
Clinical Significance